vs
ARDELYX, INC.（ARDX）与null（SWIM）财务数据对比。点击上方公司名可切换其他公司
null的季度营收约是ARDELYX, INC.的1.2倍（$117.3M vs $94.5M），null净利率更高（-7.3% vs -39.8%，领先32.5%），ARDELYX, INC.同比增速更快（27.5% vs 5.3%），过去两年ARDELYX, INC.的营收复合增速更高（13.6% vs -14.4%）
Ardelyx是一家商业化阶段的生物制药企业，专注于研发和商业化针对胃肠道、心肾及代谢类疾病的创新疗法，其核心产品已在美国获批用于治疗便秘型肠易激综合征，同时拥有涵盖多适应症的各阶段研发管线。
该企业是一家源自美国的跨国律师事务所，1934年创立于加利福尼亚州洛杉矶，在诉讼业务、公司法务以及监管合规法律领域拥有深厚的行业积累与知名度，是全球颇具影响力的综合性律所之一。
ARDX vs SWIM — 直观对比
营收规模更大
SWIM
是对方的1.2倍
$94.5M
营收增速更快
ARDX
高出22.2%
5.3%
净利率更高
SWIM
高出32.5%
-39.8%
两年增速更快
ARDX
近两年复合增速
-14.4%
损益表 — Q1 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $94.5M | $117.3M |
| 净利润 | $-37.6M | $-8.5M |
| 毛利率 | — | 31.7% |
| 营业利润率 | — | — |
| 净利率 | -39.8% | -7.3% |
| 营收同比 | 27.5% | 5.3% |
| 净利润同比 | — | -43.1% |
| 每股收益（稀释后） | $-0.15 | $-0.07 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ARDXSWIM
| Q1 26 | $94.5M | $117.3M | ||
| Q4 25 | $125.2M | $100.0M | ||
| Q3 25 | $110.3M | $161.9M | ||
| Q2 25 | $97.7M | $172.6M | ||
| Q1 25 | $74.1M | $111.4M | ||
| Q4 24 | $116.1M | $87.3M | ||
| Q3 24 | $98.2M | $150.5M | ||
| Q2 24 | $73.2M | $160.1M |
净利润ARDXSWIM
| Q1 26 | $-37.6M | $-8.5M | ||
| Q4 25 | $-407.0K | $-7.0M | ||
| Q3 25 | $-969.0K | $8.1M | ||
| Q2 25 | $-19.1M | $16.0M | ||
| Q1 25 | $-41.1M | $-6.0M | ||
| Q4 24 | $4.6M | $-29.2M | ||
| Q3 24 | $-809.0K | $5.9M | ||
| Q2 24 | $-16.5M | $13.3M |
毛利率ARDXSWIM
| Q1 26 | — | 31.7% | ||
| Q4 25 | 91.3% | 28.0% | ||
| Q3 25 | 96.4% | 35.4% | ||
| Q2 25 | 87.3% | 37.1% | ||
| Q1 25 | 83.4% | 29.5% | ||
| Q4 24 | 84.3% | 24.6% | ||
| Q3 24 | 84.0% | 32.4% | ||
| Q2 24 | 87.1% | 33.1% |
营业利润率ARDXSWIM
| Q1 26 | — | — | ||
| Q4 25 | 4.1% | -10.7% | ||
| Q3 25 | 4.2% | 13.3% | ||
| Q2 25 | -14.7% | 14.3% | ||
| Q1 25 | -49.0% | -4.4% | ||
| Q4 24 | 7.0% | -14.9% | ||
| Q3 24 | 2.3% | 8.9% | ||
| Q2 24 | -18.6% | 12.5% |
净利率ARDXSWIM
| Q1 26 | -39.8% | -7.3% | ||
| Q4 25 | -0.3% | -7.0% | ||
| Q3 25 | -0.9% | 5.0% | ||
| Q2 25 | -19.5% | 9.3% | ||
| Q1 25 | -55.5% | -5.4% | ||
| Q4 24 | 4.0% | -33.4% | ||
| Q3 24 | -0.8% | 3.9% | ||
| Q2 24 | -22.5% | 8.3% |
每股收益（稀释后）ARDXSWIM
| Q1 26 | $-0.15 | $-0.07 | ||
| Q4 25 | $-0.01 | $-0.06 | ||
| Q3 25 | $0.00 | $0.07 | ||
| Q2 25 | $-0.08 | $0.13 | ||
| Q1 25 | $-0.17 | $-0.05 | ||
| Q4 24 | $0.01 | $-0.24 | ||
| Q3 24 | $0.00 | $0.05 | ||
| Q2 24 | $-0.07 | $0.11 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $238.1M | — |
| 总债务越低越好 | $203.5M | $3.3M |
| 股东权益账面价值 | $148.6M | $396.7M |
| 总资产 | $504.5M | $856.4M |
| 负债/权益比越低杠杆越低 | 1.37× | 0.01× |
8季度趋势，按日历期对齐
现金及短期投资ARDXSWIM
| Q1 26 | $238.1M | — | ||
| Q4 25 | $68.0M | — | ||
| Q3 25 | $42.7M | — | ||
| Q2 25 | $90.0M | — | ||
| Q1 25 | $30.8M | — | ||
| Q4 24 | $64.9M | — | ||
| Q3 24 | $47.4M | — | ||
| Q2 24 | $41.9M | — |
总债务ARDXSWIM
| Q1 26 | $203.5M | $3.3M | ||
| Q4 25 | $202.8M | $279.8M | ||
| Q3 25 | $202.1M | $281.1M | ||
| Q2 25 | $201.4M | $281.5M | ||
| Q1 25 | $151.3M | $306.9M | ||
| Q4 24 | $150.9M | $281.5M | ||
| Q3 24 | $100.7M | $282.8M | ||
| Q2 24 | $100.2M | $282.4M |
股东权益ARDXSWIM
| Q1 26 | $148.6M | $396.7M | ||
| Q4 25 | $166.9M | $405.9M | ||
| Q3 25 | $154.3M | $408.4M | ||
| Q2 25 | $139.5M | $398.4M | ||
| Q1 25 | $145.7M | $381.1M | ||
| Q4 24 | $173.3M | $387.2M | ||
| Q3 24 | $158.3M | $416.6M | ||
| Q2 24 | $147.0M | $408.1M |
总资产ARDXSWIM
| Q1 26 | $504.5M | $856.4M | ||
| Q4 25 | $501.6M | $823.2M | ||
| Q3 25 | $486.2M | $844.4M | ||
| Q2 25 | $466.8M | $822.1M | ||
| Q1 25 | $410.2M | $824.6M | ||
| Q4 24 | $435.8M | $794.2M | ||
| Q3 24 | $367.9M | $853.4M | ||
| Q2 24 | $343.5M | $830.0M |
负债/权益比ARDXSWIM
| Q1 26 | 1.37× | 0.01× | ||
| Q4 25 | 1.21× | 0.69× | ||
| Q3 25 | 1.31× | 0.69× | ||
| Q2 25 | 1.44× | 0.71× | ||
| Q1 25 | 1.04× | 0.81× | ||
| Q4 24 | 0.87× | 0.73× | ||
| Q3 24 | 0.64× | 0.68× | ||
| Q2 24 | 0.68× | 0.69× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $-47.7M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流ARDXSWIM
| Q1 26 | — | $-47.7M | ||
| Q4 25 | $21.0M | $23.3M | ||
| Q3 25 | $365.0K | $51.0M | ||
| Q2 25 | $-25.3M | $36.0M | ||
| Q1 25 | $-38.5M | $-46.9M | ||
| Q4 24 | $9.8M | $6.2M | ||
| Q3 24 | $501.0K | $37.2M | ||
| Q2 24 | $-19.4M | $52.4M |
自由现金流ARDXSWIM
| Q1 26 | — | — | ||
| Q4 25 | $20.6M | $14.1M | ||
| Q3 25 | $209.0K | $45.2M | ||
| Q2 25 | $-26.0M | $29.1M | ||
| Q1 25 | $-38.8M | $-50.3M | ||
| Q4 24 | $9.2M | $-98.0K | ||
| Q3 24 | $364.0K | $33.2M | ||
| Q2 24 | $-19.5M | $47.9M |
自由现金流率ARDXSWIM
| Q1 26 | — | — | ||
| Q4 25 | 16.4% | 14.1% | ||
| Q3 25 | 0.2% | 27.9% | ||
| Q2 25 | -26.6% | 16.8% | ||
| Q1 25 | -52.3% | -45.2% | ||
| Q4 24 | 7.9% | -0.1% | ||
| Q3 24 | 0.4% | 22.1% | ||
| Q2 24 | -26.7% | 29.9% |
资本支出强度ARDXSWIM
| Q1 26 | — | — | ||
| Q4 25 | 0.3% | 9.2% | ||
| Q3 25 | 0.1% | 3.6% | ||
| Q2 25 | 0.7% | 4.0% | ||
| Q1 25 | 0.4% | 3.1% | ||
| Q4 24 | 0.5% | 7.2% | ||
| Q3 24 | 0.1% | 2.7% | ||
| Q2 24 | 0.2% | 2.8% |
现金转化率ARDXSWIM
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 6.29× | ||
| Q2 25 | — | 2.25× | ||
| Q1 25 | — | — | ||
| Q4 24 | 2.11× | — | ||
| Q3 24 | — | 6.32× | ||
| Q2 24 | — | 3.95× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ARDX
| IBSRELA | $70.1M | 74% |
| XPHOZAH | $23.3M | 25% |
| Non-cash royalty revenue related to the sale of future royalties | $695.0K | 1% |
| Product supply revenue | $354.0K | 0% |
SWIM
暂无分部数据
